Abstract. Acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology and clinical course. Until now the basis for prognostic evaluation and therapeutic decision has been the karyotype, genetic FLT3 abnormalities and the initial chemotherapy response. A question that has emerged is if extensive gene expression analysis may supplement or partly replace current diagnostics. In an attempt to address this question, we performed cDNA microarray analysis on peripheral blood samples of 25 patients with newly diagnosed AML with high blast counts. The patients were randomly selected from a large group of consecutive patients. Leaveone-out crossvalidation (LOOCV) showed with high accuracy that gene expression classifiers could predict if leukaemia samples belonged to the FAB AML-M1 or to the FAB AML-M2 groups. An unsupervised two-dimensional hierarchical cluster analysis generated 3 patient subgroups. Except for an accumulation of samples classified as FAB M1 and M2 in cluster 3, there was no evident relationship between the clusters and the FAB classification. Each subgroup displayed clearly distinguished gene expression patterns validated using realtime quantitative PCR analysis. The identification of specific gene expressions that together constitute regulatory modules must complement cluster analyses in order to achieve an accurate basis for prognosis and prediction.
Introduction
Acute myeloid leukaemia (AML) is an aggressive malignant disorder characterized by accumulation of immature myeloid progenitors in the bone marrow (1) . AML can be divided into a heterogeneous majority and the less frequent acute promyelocytic leukaemia (APL) variant characterized by promyelocyte accumulation, chromosomal translocations involving 17q21, susceptibility to differentiation induction and good prognosis (2) . The major prognostic parameters for non-APL variants are response to the initial chemotherapy cycle and the genetic abnormalities of the malignant cells (3, 4) . However, several prognostically important genetic abnormalities are associated with specific signs of differentiation in the malignant cells [e.g. inv (16) ; t(8;21)], suggesting that molecular mechanisms involved in regulation of differentiation may also contribute to the prognostic impact of these abnormalities (5) . Recent DNA microarray studies suggest that AML classification can be further improved in terms of distinguishing AML from acute lymphoblastic leukaemia (ALL) (6) (7) (8) , defining acute leukemias with MLL-abnormalities as a possible new entity separate from AML and ALL (9) and identifying new subgroups of AML with specific patterns of gene expression (10, 11) . Specific gene expression patterns are associated with prognostically important genetic abnormalities [i.e. t(8;21), inv16, t(8;21), t(15;17), 11q23-aberrations] (12) (13) (14) . Prognostic molecular markers have also been found in AML blasts with normal cytogenetics (15, 16) .
Several new therapeutic approaches are now considered in AML, including differentiation induction through inhibitors of intracellular signaling and drugs targeting gene transcription (17) . In a recent article, we emphasised the importance of collecting biological material as a part of future populationbased clinical studies of AML, and at least two approaches are possible for integration of DNA microarray analysis in future clinical studies (18) . Firstly, microarrays may be used to monitor effects of treatment, e.g. the effects of differentiationinduced therapy or therapeutic approaches targeting gene transcripts. This may imply patterns associated with the various morphologically defined subsets within both the French-American-British (FAB) and the more recent World Health Organization classification (5, 19) . Secondly, the experience from highdose cytarabine therapy has demonstrated how the genetic characteristics of malignant cells can be used for prognostic classification of AML patients (20) . DNA microarray analysis may then represent an additional approach for identification of new subsets with different responses to therapy. In the present study, we have therefore investigated native AML blasts derived from 25 patients by DNA microarray analysis. Patients were randomly selected from a larger consecutive group (21) , and sample collection as well as RNA preparation were highly standardized (18) . Despite considerable patient heterogeneity, the DNA microarray analysis allowed us to: i) identify differentiationassociated gene expression patterns; and ii) classify the patients into three major subgroups with abnormalities in the expression of genes involved in intercellular signalling, intracellular signaling, regulation of transcription, and tyrosine kinaseassociated signaling using unsupervised hierarchical cluster analysis.
Materials and methods
Patient materials. The study was approved by the local Ethics Committee and samples collected after informed consent. During the time period of 1991-2001 we collected peripheral blood AML blasts from 64 consecutive patients with high blood blast counts (21) . Cytogenetic analysis was performed for the last 48 of these 64 patients; 28 patients had a normal karyotype, 3 patients had a favourable [all inv (16) ] and 5 had an unfavourable karyotype according to the definitions used (3, 4) . A total of 98 patients with AML were admitted to our institution during the same time period. A similar karyotype distribution was also observed for the whole patient group (the last 73 of the 98 patients examined, 6 patients having a Table I . Clinical and biological characteristics of acute myeloid leukemia patients. 9 /l (normal range 3.5-10.5x10 9 /l). The WBC included at least 80% leukemia blasts.
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. We investigated AML blasts derived from 25 patients (Table I ; median age 58 years with variation range 29-83 years) that were randomly selected from the 64 consecutive patients with high peripheral blood blast counts (21) . According to the FAB classification patients were classified as AML-M0/M1 (undifferentiated, 6 patients), AML-M2 (neutrophil differentiation, 6 patients) and AML-M4/M5 (monocyte differentiation, 13 patients). One ALL sample was included as a test sample.
Preparation of AML blast. Peripheral blood samples were collected on glass tubes (sample tubes with acidum cotrosedextrose solution A; Becton-Dickinson) and leukemic peripheral blood mononuclear cells (PBMC) were isolated by density gradient separation (Ficoll-Hypaque specific density 1.077; NycoMed, Oslo, Norway;) immediately after sampling. We selected patients with a high percentage of AML blasts among the blood leukocytes (Table I) , and highly enriched AML cell populations could therefore be prepared by density gradient separation alone (>95% blast cells judged by light microscopy). Cells were frozen without delay and stored frozen in liquid nitrogen (22) . Cells were thawed and RNA prepared according to strictly standardized procedures (18) .
Microarray analysis. Total RNA was extracted according to standard protocols (23) . Synthesis of T7 RNA polymerase promoter-containing double-stranded cDNA and the generation of T7 RNA polymerase amplified RNA (cRNA) were performed as previously described (18) and according to the manufacturer's instructions (Ambion). Aminoallyl-dUTP incorporation followed by cross-coupling of Amersham Cy5-and Cy3-NHS esters was used for fluorochrome labeling of nucleic acids (18) . AML sample cRNAs and the referance cRNAs made out of a pool of 18 different cell lines (Supplementary Table I) were labelled with Cy5 and Cy3, respectively. The Human 1 cDNA Microarray system from Agilent containing 12.814 cDNA clones selected from the Incyte collection was used for the detection of gene expression in the AML samples. Hybridization and washing of the arrays were performed as recommended by Agilent (cDNA Microarray Kit Protocol). An Axon scanner recorded signal intensities at 532-and 633-nm laser lines, and the GenePix Pro software was used for feature extraction and creation of the GenePix intensity report file.
Normalization and analysis of DNA microarray data. After subtraction of background intensities for each spot, missing signals were floored using the value of 20. This procedure may include potentially interesting genes, i.e. genes that are detectably expressed only for a subset of patients, and we therefore performed data preparation using this method. The flooring of missing signals allowed us to produce log ratios for all spots, including those spots where the signal was only present in one channel. The resulting intensities were again subjected to the intra-array normalization procedure lowess and a gene expression data matrix was produced (24) . The lowess method (25) was used to correct for dye-specific effects and log-ratios calculated producing a data matrix with one row per spot (gene) and one column per sample (array). We calculated each gene's two-sample t-score in one FAB class versus the other FAB classes, thereby identifying genes most consistently high or low in one FAB class relative to the other samples. P-values corresponding to the t-scores were found using the t-distribution with n-2 degrees of freedom, where n is the number of samples included in the calculation.
Crossvalidation, validation using permutation test and twoway cluster analysis. We used a leave-one-out crossvalidation (LOOCV) with the diagonal linear discriminant (DLD) (26) approach to test whether it is possible to predict FAB class M1, M2, M4, and M5 from the gene expression data. In this analysis, the samples labelled M4-5 were excluded. Each class was treated separately and we evaluated whether a classifier could be learnt that discriminates this one class from the others. In LOOCV, one sample (patient) is held back, a classifier is learnt using data on the remaining training samples and tested on the held back sample. This procedure is repeated with each patient as test sample and the prediction accuracy is the percentage of (held back) samples that are correctly classified. In this way, we obtained prediction accuracies for each FAB class. For each class, a permutation test was performed (1000 permutations of FAB labels followed by LOOCV) to assess whether an equally good accuracy could be obtained by chance.
The gene expression differences in AML samples between FAB classes M1, M2, M4 and M5 were visualized by taking the genes with the highest t-scores for each class as input to a two-way hierarchical cluster analysis using the J-Express Pro software (www.molmine.com) (27) . We also included the two samples belonging to the AML FAB class M4-5 in the two-way cluster analysis to visualize their distribution compared to the other FAB classes.
Unsupervised cluster analysis. In order to explore possible new subtypes by analysis of the expression data, we performed an unsupervised hierarchical clustering of the 25 AML samples. For this, we selected genes with the highest variance among the AML blasts. Before clustering using J-Express Pro, the expression profile of each gene was centered by subtracting the mean over all samples for that gene. The genes and tissue were then hierarchically clustered using average linkage (WPGMA) (28) including Celera gene IDs. Hexamer-primed single-stranded cDNA corresponding to 10 ng of total RNA was diluted in TaqMan Universal buffer (Applied Biosystems) and added to each loading well. Using the above configuration each sample occupied 4-wells or one half of each card. The samples were distributed to the microwells by centrifugation for 1 min at 343 x g. The cards were sealed and placed in the ABI 7900HT Sequence Detection System using the following cycling parameters: 2 min at 50˚C, 10 min at 95˚C, and 40 alternate cycles of 15 sec at 95˚C and 60 sec at 60˚C. SDS2.2 software was applied for relative quantitation (RQ/2 -ΔΔCt ) analysis using GAPDH as normalizer and one sample as calibrator. The data were exported to Excel for further exploration and visualization.
Pathway assist analysis of molecular interactions and cellular processes. Pathway Assist is a software supplied with a molecular interaction and pathway database (ResNet), which contains 500000 links to >50000 proteins extracted from 5000000 Medline full-length articles. Selected genes from each cluster (C1-C3) were used as input genes in an analysis using Pathway Assist software v3.2 (www.ariadnegenomics. com) to explore and visualise biological pathways, molecular interaction and cellular processes characteristic for each cluster. The pathways were built by using three commands: i) direct interaction between input genes; ii) common targets for input genes; and iii) common regulators for input genes.
Results
Differential gene expression for each FAB subclass versus the other AML samples.
The gene expression profile was examined in native human AML blasts derived from 25 patients using the Human 1 cDNA Microarray from Agilent. In order to analyse the expression data for all genes, we first performed a flooring of background intensity values and calculated log 2 -ratio values based on all spots (30) . We had previously found both variation and considerable overlap between gene lists based upon either floored or filtered datasets (30) . A disadvantage with filtered data is the possible removal of genes that are expressed in only a minor subset of the tumors (30, 31) . In total, 6502 out of 12814 genes were over-or under-expressed compared to the reference probe, using a one sample t-test (29) and setting the p-value threshold to 0.05.
All arrays were selected for building a class prediction model: M1 AML (n=6), M2 AML (n=6), M4 AML (n=5), M5 AML (n=6). We calculated each gene's two-sample tscore in one FAB class versus the other FAB classes, thereby identifying the genes with the most consistent high or low expression in each FAB group compared with the remaining samples. For the 100 top scoring genes the t-scores were as follows for the different FAB classes: M1 from 10.18 to 4.02 (p-values of 1.4143E-9 to 6.1389E-4), M2 from 5.31 to 3.16 (p-values of 2.8911E-5 to 4.7359E-3), M4 from 6.02 to 3.02 (p-values of 5.6065E-6 to 6.3893E-3), M5 from 4.67 to 3.11 (p-values of 1.3043E-4 to 5.3606E-3). Considering that 12814 genes were tested, we expected some genes to be high scoring by chance. We expected 7.7 genes to score higher than 4.0, given the number of tests performed. Thus, we suspect only 8 of the 100 genes in our list for M1 to be false positives. We also expected 55 genes to score higher than 3.2, and 69.2 genes to score higher than 3.1 by chance. As a consequence of this, we expected the false discovery rate to be rather high for the gene lists for M2, M4 and M5. Still, we observe more genes than expected with high scores for these three classes.
Class prediction by use of leave-one-out crossvalidation (LOOCV).
In order to evaluate the ability of subsets of expressed genes to predict FAB subclass specificity, LOOCV was employed. The prediction accuracy did not increase when >10 genes were included (we tried 10, 20, 30, ...100). The prediction success rates were 88% for M1, 84% for M2 and 80% for M4 and 60% for M5 versus all other samples when 10 genes were included in the classifier. Prediction accuracy did not increase when >10 genes were included. It should be emphasized that, for each of the n test samples, new gene subsets were extracted based only upon the (n-1) training samples in each round of the LOOCV. In this way, it was avoided that information based upon the test sample was included in the classifiers. Classification of M1 versus non-M1, M2 versus non-M2, etc. gives an impression of the degree of separability of each FAB class from the other classes. This is a preliminary step to multiclass prediction, e.g. direct classification into categories M1, M2, M4 and M5.
Validation using random permutations of AML sample labels.
To further test the significance of the prediction accuracies achieved using LOOCV, a permutation test was performed. The FAB labels were permuted randomly followed by LOOCV as described above. Again the design was such that information did not leak from the test samples into the classifiers, which were derived from only the training set of samples. This permutation process was repeated 1000 times for each FAB subclass in order to obtain sufficient data for estimating the distribution of prediction success on random labels. The prediction success rates achieved with randomly permuted labels were then compared with that of the original correct labelling. For M1, 981 of 1000 rounds had lower prediction accuracy than the correct labelling. Using the corresponding tests for M2, M4 and M5, 960, 922 and 812 of 1000 rounds of permuted labels, respectively, gave a lower prediction accuracy than with correctly labelled samples. The permutation results gave approximate p-values of the prediction success rates obtained for the four FAB classes: 0.019 for M1, 0.040 for M2, 0.078 for M4 and 0.188 for M5. Thus, all class prediction success rates are higher than expected on average, although only significantly higher for M1 and M2.
Study of the 100 most differentially expressed genes for each FAB class. To investigate the correlations between FAB class labels and the expression profiles of the genes, we applied two-way hierarchical cluster analysis. The 100 genes were identified using a supervised analysis step where we calculated the t-score of each gene, quantifying how well it separates AML samples according to the FAB classes, and selected the top 100 from the resulting list for each FAB class. The resulting dendrogram visualises the relationships between the expression profiles of these genes and how they enable separation between the FAB classes ( Supplementary Fig. 1 ). The 100 top t-scores ranked from 10.2 to 3.1 (p-values 1.4143E-9 to 6.3893E-3, respectively). In FAB M1, only 27% of the 100 genes with the highest t-score showed overexpressed mRNAs relative to the other FAB classes. For comparison, 92% were upregulated in M2, 77% in M4 and 43% in FAB M5. More detailed information on the most consistently differentially expressed genes between FAB classes ranked by p-value is shown in Supplementary Table II. GenBank accession numbers, descriptions of genes and fold changes (D) are given.
Unsupervised hierarchical cluster analysis of AML samples.
Based upon the 500 genes with highest variance in the floored dataset, an unsupervised hierarchical clustering of the 25 samples generated three main clusters of AML samples and an outgroup close to clusters 2 and 3 ( Supplementary Fig. 2 , black). The robustness of the clusters was tested by the inclusion of various numbers of genes in the cluster analysis. The main clusters persisted although the outgroup samples redistributed in different ways when 800, 500, 250, 100 or 50 genes were used. LOOCV gave the samples of cluster 1 versus the other samples ( Supplementary Fig. 2 , blue) a prediction accuracy of 96%; samples of cluster 2 versus the other samples (purple, middle of Supplementary Fig. 2 ), a 92% accuracy; and samples of cluster 3 versus the other samples (red, right of Supplementary Fig. 2 ), a 92% accuracy. A permutation test revealed the same success or better for randomly permuted labels for 0/1000 permutations for cluster 1 and 4/1000 permutations for clusters 2 and 3. The analysis was based upon the 50 genes with the highest t-score in the model. 
Testing for association between clusters and FAB classes.
Independent validation of gene expression data using realtime quantitative PCR and flow cytometry.
Using the realtime quantitative PCR LDA format, 95 different genes were independently validated. In total, 17 of the genes in clusters C1-C3 were included in this analysis. The correspondence between gene expression according to the cDNA microarray (Agilent) and the quantitative PCR data (LDA) is displayed in Fig. 1 . Validation of CD34 expression using flow cytometry analyses of the same samples was published previously (31) .
Single genes that differed between the AML sample clusters of the unsupervised cluster analysis. In total, 76 genes exhibited a fold change between 50 and 3 for samples of one cluster compared to all other samples. In Supplementary Table III, the genes are ranked according to fold change accompanied by overall very strong p-values. Table II contains functional sorting in addition to fold change ranking. Cluster 1 samples shared a 25-to 4-fold higher expression of many immunoregulatory cytokine receptors compared to the remaining samples (Table II) . Monocyte/macrophage markers, MAC-1· (CD11b) and CYBB/gp91PHOX typically expressed in myeloid cells differentiated beyond the promyelocyte stage, were consistently upregulated in cluster 1. c-KIT mRNA was relatively strongly repressed in cluster 1 samples, while colony stimulating factor 1 receptor (CSF1R) that may substitute for KIT was overexpressed. TNFRSF1B forms a heterocomplex with TNF-receptor 1 and mediates the recruitment of two antiapoptotic proteins, c-IAP1 and c-IAP2. TNFRSF1B, BIRC1/ NAIP as well as MDR that mediate anti-apoptotic signals were Figure 1 . Correspondence between cDNA microarray and LDA gene expression. Total RNA was extracted from AML blasts and the relative mRNA expression levels were determined by qPCR TaqMan low density arrays (•, LDA) and Agilent cDNA microarrays (◊, Array). LDA analysis used GAPDH as normalizer and one sample as calibrator. GAPDH was used for normalisation of cDNA microarray values. The correlation coefficients between Array and LDA values were calculated and visualized for each of the following genes: BIRC1, CD163, IL10R1, GATA-2, KIT (cluster 1, 8 patients); CDKNA1, AML1, GATA-2 (cluster 2, 5 patients); and KIT, ITG6A, GUCY1B3 (cluster 3, 6 patients). Table II . Genes with altered expression in AML clusters 1-3.
Altered expression of genes with important common characteristics
Additional genes with altered expression 
-to 4-fold overexpressed in this cluster. For the possible functional relationship of upregulated CD163, IL10RA, HO-1 and MDR1, see Supplementary Fig. 3 and Discussion. Cluster 2 was characterized by upregulation (D=2.5-14) of several hematopoietic transcription factors. GATA-2 (D=14) is ubiquitously expressed in hematopoietic cells, with particularly high expression in early hematopoietic progenitors as well as mast cell lineages, and declines with blood cell maturation (32) . Other myeloid-specific factors that may enforce leukemisation are RUNX1, PBXIP. A striking feature of cluster 2 was an average 50-fold overexpression of carboxypeptidase A3, an enzyme associated with mast cell granules. The body's sole histamine-producing enzyme, histidine decarboxylase, was also highly upregulated in these samples (D=35.0). EGF-2 response factor, also known as butyrate response factor 2, is among the most consistently upregulated genes in cluster 2 (D=3.9).
Cluster 3 samples exhibited an average of 15-fold upregulation of CD34 mRNA, and 2.5-to 4-fold overexpression of integrin · 6 (ITGA6), coagulation factor II (thrombin) receptor (F2R), and c-KIT, all membrane molecules associated with myeloid progenitor cells. As shown in the Pathway Assist-derived Supplementary Fig. 4 , c-KIT and thrombin receptor F2R and CD34 may all activate the PI3K pathway and AKT1. The receptor tyrosine kinase c-KIT was relatively overexpressed and FLT3 was underexpressed, while tyrosine phosphatases PTPNS1 (D=5) and PTPRM (D=4) were overand underexpressed, respectively, in cluster 3 (Table II) .
Discussion
The most important prognostic parameters in AML are currently the karyotype, genetic FLT3 abnormalities and response to the initial chemotherapy course (3, 4) . These parameters probably mirror important parts of the complex epigenetic and genetic alterations in AML, and demonstrate that the peripheral AML cells comprise information that determines highly effective anti-leukemic treatment in a subset of the cases (20) . Based on the fact that most AML patients are >60 years of age, and that the overall long-term survival in AML is <50%, there is a striking need for new therapeutics with more acceptable systemic toxicity (33) . Our present study suggests that additional use of DNA microarrays can identify differentiation-associated gene expression patterns and define new patient subsets. The results thereby indicate that this approach may become useful for understanding the pathogenesis involved, for additional prognostic classification of patients and monitoring of differentiation induction therapy. We only included patients with high blast counts in the peripheral blood, and highly enriched AML blast populations could be prepared by density gradient separation of blood samples. This simple technique has a minimal risk of inducing functional alterations in the blasts [for a detailed discussion and additional references, see Bruserud et al (34) ]. Furthermore, cells were collected, separated, frozen and thawed according to strictly standardized procedures (22) .
Our patients were randomly selected from a larger group of consecutive patients with high peripheral blood blast counts (21) . Our previous study demonstrated that a normal karyotype was detected for nearly 60% of our patients, whereas favourable and unfavourable karyotypes were detected only for small patient subsets (6% and 11%, respectively) (21). This distribution is similar to other studies (3, 4, 35) except for the low frequency of favourable karyotypes that is probably due to the relatively large number of elderly patients in our study (median age 59 years) (21, 36) . Furthermore, the higher frequencies of FLT3/ITD [40% versus 27%, Bruserud et al (21) ] and D-835 mutations [20% versus 7%, Glenjen et al (37) ] among our patients may reflect our selection of patients with a high degree of leukemization.
The present study found gene expression classifiers with a significant, although not very high, ability to predict FAB subclasses of AML. Both LOOCV and permutations were used to validate the prediction accuracies. Only M1 and M2 samples had expression signatures that were strong enough for use in a classification model. One biological reason may be that samples of FAB classes M1 and M2 are more homogeneous, while FAB classes M4 and M5 contain samples of more diverse gene expression. It is not unexpected that the most striking characteristic of undifferentiated AML cells (FAB-M0/M1) was downregulation of several genes involved in cell differentiation and organ development. On the other hand, granulocytic differentiation (FAB-M2) was associated with a heterogeneous gene expression pattern with regard to molecular function. In contrast, AML cells with monocytic differentiation (FAB-M4/M5) showed altered expression of genes mainly involved in intracellular signal transduction and regulation of DNA-repair, cell cycle events or DNA transcription (Supplementary Table II) . This last observation is consistent with reports regarding essential regulation of gene expression during monocyte differentiation (38, 39) . Previous studies have reported that unsupervised cluster analysis sorted AML samples according to cytogenetic abnormalities rather than FAB phenotypes (12) and that gene expression correlates with the common AML translocations [t(8;21), t(15;17), inv (16) ], and translocations involving 11q23 have also been described (12, (40) (41) (42) . However, these abnormalities are uncommon, especially among the elderly majority of the consecutive population-based patient group. Even though we investigated highly heterogeneous patients randomly selected from a consecutive group with another distribution of cytogenetic abnormalities due to high age, our results are in agreement with these previous studies of relatively young selected patients: gene expression classifiers did not predict FAB subclasses with a very high accuracy but, according to t-scores, we were able to distinguish patients of a particular FAB subclass from the others.
Unsupervised hierarchical cluster analysis has a potential to reveal gene clusters shared by subsets of patient samples. This analysis is independent of previous sample classification such as FAB classification. Instead, the samples may segregate into new clusters or groups that share significant gene expression patterns. When the 500 genes with highest variance across the samples were selected for the unsupervised hierarchical cluster analysis, as visualized in Supplementary Fig. 2 , three main clusters of 25 AML samples resulted. In addition, four patient samples segregated as an outgroup. LOOCV and permutation tests showed that classifiers were able to predict the three main clusters of heterogeneous AML samples with a very high accuracy. Except for a significant accumulation of FAB M1 and M2 samples in cluster 3, there was no evidence that the non-supervised clustering was affected by FAB subclasses. The segregation of many M1 and M2 samples into cluster 3 therefore supports the above proposal that the M1 and M2 samples of this study may share more gene expression patterns than M4 and M5 samples. It has been pointed out that the differentiation stage of the lineage, as reflected in the FAB classification, may direct unsupervised clustering to an extent that could obscure gene expression of more critical significance for prognosis and prediction (16) . This idea is partly supported by the results described above. Supervised and unsupervised cluster analysis may therefore have to be supplemented by directed search and identification of expression of a number of genes that together constitute a critical regulatory module. In the future, the identification of precisely characterized modules of genes may provide the best targets for tailored treatment. We present several putatative gene expression modules.
The expression of a number of genes in clusters 1, 2 and 3 (Table II and Supplementary Table III) appears relevant for the pathogenesis of AML. When several consistently regulated genes fit together into one regulatory module, the probability of functional relevance is high compared to observations on single genes. This is exemplified in cluster 1 by the relative overexpression of CD163 (D=12) and IL10RA (D=10). Although not previously described in AML, there are several reports that CD163 and IL-10 may be involved in a regulatory loop (43) (44) (45) that leads to heme oxygenase 1 (HO-1) induction (46, 47) . Examination of the 100 top scoring genes revealed that HO-1 is indeed consistently upregulated (D=8.6, p=2.8274E-4) in cluster 1 samples. Recently, resistance to apoptosis has been reported in gastric cancer cells with elevated HO-1 and c-IAP2 activity (48) . We noticed that NAIP/BIRC1 (IAP repeatcontaining 1) was also overexpressed (D=4, p=7.5774E-4) in cluster 1 (Supplementary Fig. 3 ). It is therefore of interest to further explore whether the IL-10, CD163, HO-1 regulatory module has been diverted and selected to counteract terminal differentiation and apoptosis (49) and thus enhance the proliferation and survival of these AML blasts. Another pathway that may be specifically activated in this group of AML patients is the NF-κB pathway indicated by upregulation of NF-κB-targeted genes such as ICAM-1, IL-6, TNFRSF1B and NAIP (50) .
Altered expression of genes encoding transcription and chromatin condensation and cell cycle regulation factors was common for cluster 2 samples. Increased expression of the GATA-2, RUNX1, CBX7, cyclin A1 and defender against cell death 1 (DAD1) and repression of NCF2 (D=11) that is transcribed exclusively in myeloid cells that have differentiated beyond the promyelocyte stage, may contribute to leukemisation of hematopoietic cells with normal cytogenetics.
In cluster 3, hematopoietic stem cell marker CD34 mRNA was highly expressed. Attempts have been made to define a core gene expression pattern associated with stem cells ('stemness') (51, 52) . This concept has met with difficulty since there is very little overlap between gene lists extracted by three different groups in order to define 'stemness' (53, 54) . A comparison of three independently derived lists of 'stemness' genes showed only one common gene, integrin · 6 (ITGA6), in the three studies (54) . Intriguingly, this particular gene (ITGA6, p=5.8212E-5) is the second most consistently upregulated gene in cluster 3. CD34, KIT and thrombin receptor have all been associated with stem cell expression (55) and were all consistently and highly overexpressed in cluster 3 (Table II) suggesting that samples of cluster 3 share important features associated with gene expression of early myeloid precursors and possibly bone marrow stem cells ( Supplementary Fig. 4) .
Cluster 1 to cluster 3 subsets defined by unsupervised cluster analysis indicate that patient subpopulations may differ with regard to pathogenesis. Cluster 1 was characterized by altered expression of several soluble mediators and membrane molecules, including receptors for immunoregulatory cytokines, which may in turn activate anti-apoptotic genes and genes that mediate drug resistance. Cluster 2 (patients with normal cytogenetics) was characterized by altered expression of genes encoding the transcription/cell cycle machinery and intracellular signaling molecules. The characteristic pattern of receptor tyrosine kinase and phosphatase expression of cluster 3 samples was striking, including a prominent KIT/FLT3 (56) expression ratio in combination with downregulation of the tyrosine phosphatase PTPNS1. Such patterns may be helpful in the pursuit of new therapeutic approaches.
To conclude, our present results demonstrate that gene expression profiles can be used to: i) characterize the differentiation status of native human AML cells; and ii) define new subsets among highly heterogeneous AML patients. We suggest that supervised and unsupervised cluster analyses will have to be complemented with exact identification of regulatory gene modules that may or may not segregate into specific clusters. The new tools for global analysis of gene expression supplemented with appropriate validation and experiments have the potential to achieve this goal.
Supplementary Figure 1 . Two-way cluster analysis of AML samples. Supervised two-way cluster analysis based upon 100 genes with top t-scores discriminating patients of FAB classes M1 (blue), M2 (violet), M4 (red) and M5 (green). The two samples classified as FAB M4-5 are included in the two-way cluster analysis (black). The corresponding p-values of the genes characteristically expressed in M1, M2. M4 and M5 ranged from 1.4143E-9 to 6.3893E-3. Gene clusters are indicated by vertical bars and a few selected genes of each cluster were extracted and highlighted in the same colour. Supplementary Figure 2 . Unsupervised two dimensional hierarchical cluster analysis of gene expression in AML. Unsupervised two dimensional hierarchical cluster analysis of different FAB classes based upon 500 of 12814 genes with highest variance. The clustering defines three sample clusters: cluster 1 (blue), cluster 2 (purple), cluster 3 (red). The gene profiles were centered by subtracting the mean before clustering. Characteristic genes of each cluster are indicated to the right. Supplementary Table II . Genes that separate the AML FAB classes. 
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C, Differential expressed genes in AML cluster 3 (C3) GenBank Gene symbol Gene name Relative gene expression p-value D 
D is relative gene expression.
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